Lumos Diagnostics has released its Quarterly Report & 4C for the period ending 30 June 2024.
Key Highlights from the Fourth Quarter include:
- Positive cash flow for the quarter of US$3.1 million, with the cash balance as at 30 June 2024 of US$6.5 million.
- Unaudited revenue of US$4.3 million for the quarter, up 8% compared to the prior quarter (Q3 FY24 - US$4.0 million).
- Unaudited revenue of US$11.1 million for FY24, up 6% compared to the prior FY23 year of US$10.5 million.
- The Services business grew strongly through the quarter, with revenue up 21% on Q3.
- Cash receipts of US$7.4 million for the quarter (Q3 FY24 US$6.7 million), including US$5.0 million non-refundable payment from Hologic under the IP Agreement.
- Key “Phase 1 Milestone” of the Hologic fFN Development Agreement achieved and the US$0.4 million milestone payment received.
- Post reporting date, Lumos expanded its FebriDx distribution agreements with Henry Schein in Australia, New Zealand and Belgium.
Lumos CEO, Doug Ward noted:
“It was pleasing to see our efforts rewarded in the second half of FY24, with the momentum continuing to build. The Hologic Agreement, announced in January 2024, helped position Lumos on a solid footing. Supported by positive cashflow generation in the final two quarters of the year, our balance sheet finished in great shape with US$6.5 million cash in the bank. I am very optimistic about the future outlook for Lumos and look forward to providing further positive updates to the market over the course of the year.”
Click here to read the ASX release.